Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Broader equities have been relatively volatile over the past few months. In an environment like this, it's best to prioritize investing in well-established, profitable corporations. While small-cap stocks may have higher upside potential than much larger companies, the risks they entail often make them not worth investing in. With that as a backdrop, let's consider one smaller company that has performed pretty well over the trailing-12-month period, but isn't worth your time: Amarin (NASDAQ: AMRN) . Instead of betting on this small drugmaker, it's best to put your hard-earned money into a pharmaceutical leader like Novartis (NYSE: NVS) instead. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Amarin's prospects are bleak Amarin's shares have climbed about 22% over the past year.
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc. [Yahoo! Finance]Yahoo! Finance
- Beacon Therapeutics appoints Ryan Robinson as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas [Yahoo! Finance]Yahoo! Finance
- OCT West Coast: China's clinical trial infrastructure delivers upto 60% cost savings [Yahoo! Finance]Yahoo! Finance
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 2/12/26 - Form 144
- 2/9/26 - Form 144
- 2/4/26 - Form S-8
- NVS's page on the SEC website